Multicenter Observational Study of CTR-CVT

Multicenter Observational Study of Cancer Therapy Related Cardiovascular Toxicity

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030260245

Enrollment

900000

Registered

2026-06-23

Start date

2026-06-23

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Therapy Related Cardiovascular Toxicity

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have developed, or are suspected to have or be at risk for, any of the following cancer therapy related cardiovascular adverse events from 2011 to 2025: 1. Cardiac dysfunction (heart failure, myocardial injury, including myocarditis) 2. Arrhythmias 3. Venous thromboembolism 4. Arterial thromboembolism 5. Hypertension

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
1. Composite of Major Adverse Cardiac Events (Cardiac events include HF admission and death. 2. Changes in cardiac function over time 3. Time to cancer related death 4. Proportion of patients who discontinue or interrupt cancer therapy	—

Contacts

Public ContactTakuro Imaoka

National Cancer Center Hospital East

timaoka@east.ncc.go.jp+81-4-7133-1111

Outcome results